{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:45:47Z","timestamp":1780505147126,"version":"3.54.1"},"reference-count":29,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,4,8]],"date-time":"2012-04-08T00:00:00Z","timestamp":1333843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Transplantation"],"published-print":{"date-parts":[[2012,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>Pneumocystis<\/jats:italic> pneumonia (<jats:styled-content style=\"fixed-case\">PCP<\/jats:styled-content>) is associated with significant morbidity and mortality in renal transplant recipients (<jats:styled-content style=\"fixed-case\">RTR<\/jats:styled-content>). Trimethoprim\u2013sulfamethoxazole (<jats:styled-content style=\"fixed-case\">TMP<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">SMZ<\/jats:styled-content>) is considered the prophylactic agent\u2010of\u2010choice. Some patients require an alternative owing to <jats:styled-content style=\"fixed-case\">TMP<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">SMZ<\/jats:styled-content> intolerance. This is the first evaluation of full\u2010dose atovaquone vs. <jats:styled-content style=\"fixed-case\">TMP<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">SMZ<\/jats:styled-content> for <jats:styled-content style=\"fixed-case\">PCP<\/jats:styled-content> prevention in <jats:styled-content style=\"fixed-case\">RTR<\/jats:styled-content>. One hundred and eighty\u2010five <jats:styled-content style=\"fixed-case\">RTR<\/jats:styled-content> were evaluated in this single\u2010center, retrospective analysis. Patients received either single\u2010strength <jats:styled-content style=\"fixed-case\">TMP<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">SMZ<\/jats:styled-content> daily (group <jats:styled-content style=\"fixed-case\">I<\/jats:styled-content>; n\u00a0=\u00a0160) or 1500\u00a0mg\/d of atovaquone and of a fluoroquinolone for one\u00a0month (group <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content>; n\u00a0=\u00a025). The primary endpoint was the incidence of <jats:styled-content style=\"fixed-case\">PCP<\/jats:styled-content> at 12\u00a0months post\u2010transplant. There were no cases of <jats:styled-content style=\"fixed-case\">PCP<\/jats:styled-content> in either group. There were comparable rates of infections from bacterial pathogens and cytomegalovirus, but rates of <jats:styled-content style=\"fixed-case\">BK<\/jats:styled-content> viremia were significantly higher in group <jats:styled-content style=\"fixed-case\">I<\/jats:styled-content> (22.5%) vs. group <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> (4%; p\u00a0=\u00a00.03). The incidence of leukopenia was similar in both groups. Higher mean potassium levels were seen in group <jats:styled-content style=\"fixed-case\">I<\/jats:styled-content> at three\u00a0months post\u2010transplant but were comparable at all other time points. The need for dose reduction and\/or premature discontinuation of therapy secondary to adverse events was more prevalent in <jats:styled-content style=\"fixed-case\">TMP<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">SMZ<\/jats:styled-content>\u2010treated patients. In our experience, atovaquone appears to be effective in preventing <jats:styled-content style=\"fixed-case\">PCP<\/jats:styled-content> post\u2010renal transplant and also demonstrates good tolerability.<\/jats:p>","DOI":"10.1111\/j.1399-0012.2012.01624.x","type":"journal-article","created":{"date-parts":[[2012,4,9]],"date-time":"2012-04-09T01:06:23Z","timestamp":1333933583000},"source":"Crossref","is-referenced-by-count":37,"title":["Atovaquone versus trimethoprim\u2013sulfamethoxazole as <i><scp>P<\/scp>neumocystis jirovecii<\/i> pneumonia prophylaxis following renal transplantation"],"prefix":"10.1111","volume":"26","author":[{"given":"Steven","family":"Gabardi","sequence":"first","affiliation":[{"name":"Department of Transplant Surgery Brigham and Women's Hospital Boston MA USA"},{"name":"Department of Pharmacy Services Brigham and Women's Hospital Boston MA USA"},{"name":"Renal Division Brigham and Women's Hospital Boston MA USA"},{"name":"Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Millen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services Brigham and Women's Hospital Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Hurwitz","sequence":"additional","affiliation":[{"name":"Harvard Medical School Boston MA USA"},{"name":"Center for Clinical Investigation Brigham and Women's Hospital Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy New\u2010York Presbyterian Hospital New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keri","family":"Roberts","sequence":"additional","affiliation":[{"name":"Department of Transplant Surgery Brigham and Women's Hospital Boston MA USA"},{"name":"Department of Pharmacy Services Brigham and Women's Hospital Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Chandraker","sequence":"additional","affiliation":[{"name":"Renal Division Brigham and Women's Hospital Boston MA USA"},{"name":"Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,4,8]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid0809.020096"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.19.2450"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.5.995"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3062.2003.00018.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1086\/515126"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.17.4.770-782.2004"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-198606000-00012"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.4065\/71.1.5"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2004.12.085"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116896"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra064928"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1086\/504811"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1086\/323129"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02914.x"},{"key":"e_1_2_6_16_1","unstructured":"Dapsone [package insert].Princeton NJ:Jacobus Pharmaceuticals; Revised August 2009. In;2009."},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.01079.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0306-3623(95)00029-1"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.3109\/03602539509029818"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/lt.500030207"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e3180a6af55"},{"key":"e_1_2_6_22_1","unstructured":"NebuPent [package insert].Schaumburg IL:APP Pharmaceuticals; Revised February 2008. In;2008."},{"key":"e_1_2_6_23_1","unstructured":"Mepron [package insert].Research Triangle Park NC:GlaxoSmithKline; Revised May 2008. In;2008."},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702004"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812243392604"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/135965350701200104"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.08261109"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2001.26433"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1086\/383150"},{"key":"e_1_2_6_30_1","volume-title":"Pharmacy's Fundamental Reference","author":"2010 Red Book","year":"2010"}],"container-title":["Clinical Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-0012.2012.01624.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-0012.2012.01624.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T13:39:27Z","timestamp":1698759567000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-0012.2012.01624.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,8]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["10.1111\/j.1399-0012.2012.01624.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-0012.2012.01624.x","archive":["Portico"],"relation":{},"ISSN":["0902-0063","1399-0012"],"issn-type":[{"value":"0902-0063","type":"print"},{"value":"1399-0012","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,8]]}}}